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Summary Expression of pancreatic trypsinogen and cathepsin B in 23 surgically resected pancreatic ductal
adenocarcinomas was evaluated immunohistochemically, using a monoclonal antibody against human pan-
creatic trypsinogen and a polyclonal antibody against human cathepsin B. Fifteen of 20 invasive tubular
adenocarcinomas (75%) expressed pancreatic trypsinogen in a coarse granular pattern located in the sup-
ranuclear cytoplasm of the carcinoma cells. In addition, metastatic lesions, including those in peripancreatic
lymph nodes and neural plexuses, expressed pancreatic trypsinogen. In contrast, three intraductal (non-
invasive) papillary adenocarcinomas did not express pancreatic trypsinogen. Cathepsin B expression was
recognised in 14 of 20 invasive tubular adenocarcinomas (70%) in a fine granular pattern located diffusely in
the cytoplasm of the carcinoma cells, while none of the three intraductal papillary adenocarcinomas had
detectable cathepsin B. These findings suggest that pancreatic invasive ductal adenocarcinomas express
pancreatic trypsinogen and cathepsin B immunoreactive peptides, raising the possibility that pancreatic
trypsinogen and cathepsin B may act independently of each other in the process of carcinoma invasion and
metastasis, like other different classes of proteases involved in the proteolytic modification of the matrix
barrier.
Pancreatic trypsinogen is one of the proteolytic enzymes
produced by pancreatic acinar cells. A recent study
(Miszczuk-Jamska et al., 1991) has shown that a new human
pancreatic adenocarcinoma cell line (CFPAC-1) and a
previously established human pancreatic carcinoma cell line
(CAPAN-1) produce human pancreatic trypsinogen. This
enzyme is a target protease for pancreatic secretory trypsin
inhibitor (PSTI). Tumour-associated trypsinogen is also
known to be a serine protease produced by malignant
tumour cells, and is believed to play an essential role in
cancer invasion and metastasis by degrading trypsin-sensitive
extracellular matrix components (Tryggvason et al., 1987;
Koivunen et al., 1991a). Tumour-associated trypsinogen has
been identified as a target protease for a tumour-associated
trypsin inhibitor (TATI), also referred to as PSTI (Huhtala et
al., 1982; Halila et al., 1988; Stenman et al., 1988). A recent
study (Koivunen et al., 1989) has shown that tumour-
associated trypsinogen and pancreatic trypsinogen are similar
with respect to amino-terminal sequence, molecular weight
and immunoreactivity, but that significant differences exist
with respect to isoelectrophoretic mobility and stability.
Therefore, it is possible that pancreatic trypsinogen may also
take part in the protease cascade associated with tumour
invasion and metastasis. It is currently not known whether
the differences between tumour-associated trypsinogen and
pancreatic trypsinogen are a result of tissue-specific tryp-
sinogen modification or distinct genes.
We have therefore evaluated the presence or absence of
pancreatic trypsinogen immunohistochemically in 23 sur-
gically resected pancreatic ductal adenocarcinomas. In addi-
tion, we have evaluated the expression of cathepsin B, which
is a lyosomal cysteine protease and is involved in several
physiological and biological functions, such as activation of
proenzymes and prohormones (Greenbaum et al., 1959; Bansal
et al., 1980) and degradation of extracellular matrix (Recklies
et al., 1980; Sloane, 1990).
Materials and methods
Tissue specimens
The current study included 23 surgically resected pancreatic
ductal adenocarcinomas between 1989 and 1991. Twenty of
the tumours were histologically proven to be pancreatic
invasive tubular adenocarcinoma, while the other three
represented an intraductal variant of pancreatic papillary
adenocarcinoma without stromal invasion (Conley et al.,
1987). There were no cases of periampullary tumours or
distal bile duct tumours not originating from the pancreatic
duct. The patients included 16 men and seven women, rang-
ing from 33 to 77 years of age, with a mean age of 62 years.
After careful gross description of the primary tumour, the
resected specimens with attached peripancreatic lymph nodes
and neural plexuses were routinely fixed in 10% neutral-
buffered formalin and embedded in paraffin. After fixation
for 7-10 days, the specimens were cut into 5 mm stepwise
tissue sections. In the present study, three or more represen-
tative sections, including areas of non-malignant pancreatic
tissue, were subjected to immunohistochemical staining as
described below. Mouse monoclonal antibody against human
pancreatic trypsinogen (Chemicon International, Tomecula,
CA, USA) and sheep polyclonal antibody against human
cathepsin B (Binding Site, Birmingham, UK) were used. In
addition, corresponding metastatic lesions, including 18
peripancreatic lymph nodes and five peripancreatic neural
plexuses, selected from five patients with carcinoma invasion
were evaluated.
Histological findings were evaluated according to the
General Rules for Cancer of the Pancreas proposed by the
Japanese Pancreatic Society (1986). Three patients were stage
I, two were stage II, 12 were stage III and six were stage IV.
The adenocarcinoma was well differentiated in nine patients,
moderately differentiated in 13 and poorly differentiated in
one.
Immunohistochemical studies
Pancreatic trypsinogen and cathepsin B were immunohis-
tochemically identified by the three-step indirect immuno-
peroxidase method (streptavidin-biotin-peroxidase complex).
Briefly, sections were deparaffinised by graded xylene and
alchohol, and subsequently immersed in absolute methanol
containing 0.3% hydrogen peroxide to block endogenous
peroxidase activity. Following a phosphate-buffered saline
(PBS) rinse, the sections were covered with normal goat or
rabbit serum at a 1:30 dilution for 30 min at room
temperature to block non-specific binding. Monoclonal
antibody against human pancreatic trypsinogen (diluted to
1:100) or polyclonal antibody against human cathepsin B
(diluted to 1:50) was added at 4°C overnight. The sections
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were then treated with biotinylated goat anti-mouse IgG
(Dakopatts, Copenhagen, Denmark) or with biotinylated
rabbit anti-sheep IgG (Dakopatts) for 30 min. The strep-
tavidin-biotin-peroxidase complexes (Dakopatts) were then
added to the sections for 30 min at room temperature. Reac-
tion products were developed by immersing the sections in
3.3'-diaminobenzidine tetrahydrochloride solution containing
0.1% hydrogen peroxide. Slides were lightly counterstained
with methyl green.
Specificity ofimmunostaining
In each immunostaining run, the primary antibody was
replaced by non-immune serum (normal mouse or sheep
serum) (Dako, Santa Barbara, CA, USA) or PBS; this was
followed by the immunohistochemical procedure described
above. An absorption test was also performed in selected
specimens during each immunostaining procedure. In pan-
creatic,trypsinogen immunostaining, human pancreatic tryp-
sin (Athens Research, Athens, GA, USA) was mixed with the
pancreatic trypsinogen antibody solution. The solution mix-
ture was incubated at 4°C overnight and centrifuged at
4,000 r.p.m. for 10 min. The supernatant was collected and
used as the primary antibody in immunostaining. Similar
procedures were performed in cathepsin B immunostaining
using human cathepsin B (Athens Research) as the absor-
bent. As positive controls for pancreatic trypsinogen and
cathepsin B, sections from normal pancreatic and liver tissue
specimens were used respectively.
Immunohistochemical quantification ofstaining with pancreatic
trypsinogen or cathepsin B
The intensity of staining for pancreatic trypsinogen or
cathepsin B was estimated semiquantitatively as follows: (-)
denotes no reaction, mild (+) denotes less than 30% of cells
positive, moderate (+ +) denotes 30-70% of cells positive,
and marked (+ + +) denotes more than 70% of cells
positive.
Statistics
The results of the immunohistochemical study were evaluated
using the chi-square test. A difference was considered to be
significant when the P-value was <0.05.
Results
Pancreatic trypsinogen immunohistochemistry
Monoclonal antibody specificity Pancreatic trypsinogen was
identified in acinar cells of normal pancreas but was not
present in islet cells or epithelia or pancreatic ducts (Figure
1). Staining was negative when non-immune serum, PBS or
absorbed primary antibody was used in the first reaction.
Primary tumours Table I summarizes the immunohisto-
chemical quantification of pancreatic trypsinogen in 23
primary pancreatic ductal adenocarcinomas. Fifteen of 20
invasive tubular adenocarcinomas (75%) displayed mild to
marked immunoreactivity to pancreatic trypsinogen (Figure
2a). The immunoreactive pattern was coarsely granular, and
was generally present in the supranuclear cytoplasm of the
carcinoma cells (Figure 2b). The remaining five invasive
adenocarcinomas (25%) were negative for pancreatic tryp-
sinogen. There was no significant correlation between tumour
differentiation and pancreatic trypsinogen expression. Stain-
ing for pancreatic trypsinogen in the acinar cells of adjacent
non-malignant tissues was similar in intensity to that in the
primary carcinoma cells. In contrast, three intraductal (non-
invasive) papillary adenocarcinomas did not express pan-
creatic trypsinogen, while adjacent normal acinar cells
stained intensely (Figure 3). The intensity of pancreatic
trypsinogen immunoreactivity showed heterogeneity both
Figure 1 Immunohistochemical identification of pancreatic tryp-
sinogen. It is expressed in acinar cells but not in islet cells or
pancreatic duct epithelia of normal pancreas (original
magnification x 100).
between and within cases. Usually it was more pronounced at
the infiltrative margins of the tumours.
Associated metastatic lesions Most carcinoma cells in the
peripancreatic neural plexuses were stained intensely with
antibody to pancreatic trypsinogen in all five cases, as seen in
primary lesions (Figure 4a). Eighteen metastatic peripanc-
reatic lymph nodes also showed an intense immunoreactivity
for pancreatic trypsinogen (Figure 4b).
Cathepsin B immunohistochemistry
Polyclonal antibody specificity Cathepsin B was identified in
normal hepatocytes. Staining was negative when non-immune
serum, PBS or absorbed primary antibody was used in the
first reaction.
Primary tumours The immunohistochemical quantification
of cathepsin B in 23 primary pancreatic ductal adenocar-
cinomas is summarised in Table I. Fourteen of 20 invasive
tubular adenocarcinomas (70%) showed mild to moderate
immunoreactivity to cathepsin B (Figure 5), but all three
intraductal papillary adenocarcinomas failed to express
cathepsin B. Fibroblasts adjacent to the carcinoma cells
reacted intensely. The immunoreactive pattern was finely
granular, and was generally present diffusely in the cytoplasm
of carcinoma cells and fibroblasts. The staining intensity
varied greatly even in the same microscopic area. In some
cases, cathepsin B immunoreactivity was more pronounced at
the infiltrative margins of the tumours. There was no
significant correlation between tumour differentiation and
cathepsin B expression.
Associated metastatic lesions In all five cases, staining of
carcinoma cells in the peripancreatic neural plexuses was
sparse and weak, with antibody to cathepsin B. Fifteen of 18
metastatic peripancreatic lymph nodes (83.3%) showed weak
to moderate cathepsin B expression in the cytoplasm.
Discussion
This study demonstrates the presence of pancreatic tryp-
sinogen in primary pancreatic ductal adenocarcinomas and
associated metastatic lesions, as well as in adjacent normal
acinar cells. Pancreatic trypsinogen immunoreactivity in pan-
creatic ductal adenocarcinoma was specific, since it was
abolished by preabsorption of the primary antibody. This
preliminary study suggests that these carcinoma cells produce
pancreatic trypsinogen immunoreactive peptides. However, 5
of 20 invasive ductal adenocarcinomas (25%) did not exhibit154 T. OHTA et al.
Table I Immunohistochemical identification ofpancreatic trypsinogen and cathepsin B in 23 pancreatic
ductal adenocarcinomas
Presence of
Presence ofpancreatic trypsinogen cathepsin B
Age (years) Primary tumour Associated nomal in primary
Patient no. sex Histological type cells acinar cells tumour cells
Invasive ductal adenocarcinoma
1 54/F Moderately diff. tub. (+ + +) (+ + +) (+)
2 59/M Moderately diff. tub. (+ + +) (+ + +) (+ +)
3 64/M Moderately diff. tub. (+ + +) (+ + +) (+ +)
4 66/M Moderately diff. tub. (+ + +) (+ + +) (+)
5 76/F Moderately diff. tub. (+ + +) (+ + +) (+)
6 63/M Moderately diff. tub. (+ + +) (+ + +) (+)
7 74/M Moderately diff. tub. (+ + +) (+ + +) (-)
8 57/M Well-diff. tub. (+ + +) (+ + +) (+)
9 61/M Well-diff. tub (+ + +) (+ + +) (+ +)
10 61/M Moderately diff. tub. (+ +) (+ +) (+)
11 77/F Well-diff. tub. (+) (+) (+)
12 70/F Well-diff. tub (+) (+) (+)
13 62/M Well-diff. tub (+) (+) (+)
14 33/M Moderately diff. tub. (+) (+) (+)
15 57/M Poorly diff. tub. (+) (+) (+)
16 55/M Moderately diff. tub. (-) (-) (-)
17 66/M Moderately diff. tub. (-) (-) (-)
18 52/F Moderately diff. tub. (-) (-) (-)
19 67/M Moderately diff. tub. (-) (-) (-)
20 51/M Well-diff. tub (-) (-) (-)
Non-invasive ductal adenocarcinoma
21 72/F Well-diff. pap. (-) +++ +) (-)
22 58/M Well-diff. pap. (-) +++ +) (-)
23 62/F Well-diff. pap. (-) (+ + +) (-)
Abbreviations: diff., differentiated; tub., tubular adenocarcinoma; pap., papillary adenocarcinoma.
Immunohistochemical finding is semiquantitatively estimated as follows: (-), no reaction; (+), less than
30% of cells positive; (+ +), 30-70% of cells positive; and (+ + +), more than 70% of cells positive.
b
Figure 2 Immunohistochemical identification of pancreatic tryp-
sinogen in invasive tubular adenocarcinomas of the pancreas. A
coarse granular pattern of expression can be seen in the sup-
ranuclear cytoplasm of the carcinoma cells (original
magnification a, x 40; b, x 160).
Figure 3 Immunohistochemical identification of pancreatic tryp-
sinogen in non-invasive papillary adenocarcinoma. Pancreatic
trypsinogen immunoreactivity is not seen in the carcinoma cells,
while the adjacent normal acinar cells are stained intensely
(original magnification x 100).
pancreatic trypsinogen immunoreactivity. It seems likely that
these specimens were compromised by delayed fixation fol-
lowing surgery, because the adjacent normal acinar cell also
failed to display pancreatic trypsinogen by the assay
utilised.
Only a few previous studies (Marks et al., 1984; Moro-
hoshi et al., 1989) have evaluated pancreatic trypsinogen in
normal and neoplastic pancreatic tissues. These studies found
no evidence for the presence of pancreatic trypsinogen in
either well-differentiated or undifferentiated pancreatic
adenocarcinomas. Our data therefore represent the first
indication of pancreatic trypsinogen expression within car-
cinoma cells from tissue, and are supported by another study
(Miszczuk-Jamska et al., 1991) which demonstrates pan-
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Figure 4 Immunohistochemical identification of pancreatic tryp-
sinogen in metastatic lesions. a, Peripancreatic neural plexus
invaded by carcinoma (original magnification x 120). b, Metas-
tatic lymph node (original magnification x 100).
Figure 5 Immunohistochemical identification of cathepsin B in
invasive tubular adenocarcinoma of the pancreas. A fine granular
pattern of expression can be seen diffusely in the cytoplasm of the
carcinoma cells. Fibroblasts (arrows) surrounding the carcinoma
cells are also positive for cathepsin B (original magnification
x 200).
adenocarcinoma cell lines (CFPAC-1 and CAPAN-1). These
apparently conflicting data on pancreatic trypsinogen expres-
sion in pancreatic ductal adenocarcinoma may be caused by
differing specificity of the pancreatic trypsinogen antibodies
used and differences in the immunohistochemical technique.
In addition, we think that the immunoreactive peptides
which are synthesised by carcinoma cells may not be present
in the form of zymogen granules, unlike the trypsinogen in
pancreatic acinar cells. Since it has been noted that zymogen
granules are not present in any duct cell-type adenocar-
cinomas (Cubilla & Fitzgerald, 1978), pancreatic trypsinogen
in malignant cells may not be processed in the normal
way.
It is noteworthy that, while 75% of the invasive tubular
adenocarcinomas displayed intense immunoreactivity for
pancreatic trypsinogen, none of the three intraductal (non-
invasive) papillary adenocarcinomas was positive. In addi-
tion, metastatic lymph node and peripancreatic neural plexus
lesions expressed pancreatic trypsinogen intensely. It is
reasonable to speculate that pancreatic trypsinogen peptides
produced by pancreatic carcinomas may play a significant
role in the degradation of extracellular matrix components,
resulting in facilitation of tumour invasion and metastasis. It
should be noted that this entity is distinct from a recently
described tumour-associated trypsinogen (Koivunen et al.,
1991a, b). Moreover, the changes observed in the present
study may be explicable on the basis of the cell of origin of
the tumour, because it is considered that pancreatic invasive
ductal adenocarcinomas probably arise from small-sized pan-
creatic ducts or centroacinar cells (Pour, 1985, 1988), whereas
the so-called intraductal adenocarcinomas of the pancreas
probably arise from large-sized pancreatic ducts (Conley et
al., 1987; Rickaert et al., 1991).
Cathepsin B is a lysosomal cysteine protease involved in
several physiological and biological functions, such as activa-
tion of proenzymes (Greenbaum et al., 1959) and degrada-
tion of extracellular matrix components (Recklies et al., 1980;
Sloane, 1990). Cathepsin B is localised primarily in the
lysosomal fraction of normal tissues in a 30-35 kDa precur-
sor form, although activity has also been measured in the
plasma membrane fraction of some tumour cells in a 20-kDa
mature form (Pietras & Roberts, 1981; Gavanaugh et al.,
1983; Koppel et al., 1984; Sloane et al., 1986; Rozhin et al.,
1987; Erdel et al., 1990; Weiss et al., 1990). Release of
cathepsin B from tumour cells into the plasma membrane
and extracellular matrix may be due to a defect in intracel-
lular processing. Mort and Recklies (1986) found that a
mature form of cathepsin B was released from breast tumour
cells. Additionally, Weiss et al. (1990) detected cathepsin B in
a well-defined granular pattern in the cytoplasm of non-
invasive tumour cells which appeared to be localised to
lysosomes, while cathepsin B expression in invasive tumour
cells seemed to be less intense and more diffuse, suggesting
that it may have been redistributed to the plasma membrane.
Our study demonstrates the presence of cathepsin B in pan-
creatic invasive ductal adenocarcinomas and in fibroblasts
surrounding the carcinoma cells with an immunoreactive pat-
tern similar to that detected in the invasive tumour cells
studied by Weiss et al. (1990). Therefore, there is a possibility
that both pancreatic trypsinogen and cathepsin B may act
independently of each other in the process of cancer invasion
and metastasis, like other different classes of proteases
involved in the proteolytic modification of the matrix bar-
rier.
It is not clear how the pancreatic trypsinogen peptides are
activated, because this protease is thought to be released into
the extracellular matrix of carcinoma cells in an inactive
form. Activation of this protease is an important regulatory
step in the degradation of the extracellular matrix. At least
three possible mechanisms can be postulated. These include
autoactivation (Colomb et al., 1979), activation by cathepsin
B (Greenbaum et al., 1959) and activation by duodenal
enterokinase or enteropeptidase refluxed into the pancreatic
duct (McCutcheon, 1968; Hadorn et al., 1974) or absorbed
into the portal circulation (Talbot et al., 1984). In addition,
human pancreatic trypsinogen occurs as two variants differ-
ing slightly from one another in biochemical properties such
as isoelectric point, susceptibility to inhibitors and substrate
specificity (Rinderknecht & Geokas, 1973). Therefore, it will
be important to determine which isoform may play a role in
tumour invasion and metastasis.156 T.:OHTA et al.
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